Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | GRK2 | P25098 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21614777 | 0.80 | CYP3A4 (0.54) | CYP2C19CYP3A4GRK2PDE10A | |
| SCHEMBL21614660 | 0.79 | CYP2C19 (0.63) | CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL21614661 | 0.79 | CYP2C19 (0.57) | CYP2C19CYP3A4GRK2CYP2C9TAS2R14 | |
| SCHEMBL21612024 | 0.78 | CYP2C19 (0.55) | CYP2C19CYP3A4GRK2PDE10ACYP2C9 | |
| SCHEMBL21614678 | 0.77 | CYP2C19 (0.53) | CYP2C19CYP3A4GRK2PDE10ACYP2C9 | |
| SCHEMBL21614707 | 0.76 | CYP2C19 (0.55) | CYP2C19CYP3A4GRK2CYP2C9LOXL2 | |
| SCHEMBL21614677 | 0.76 | CYP2C19 (0.60) | CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL21611952 | 0.76 | CYP3A4 (0.55) | CYP2C19CYP3A4GRK2CYP2C9 | |
| SCHEMBL21612013 | 0.76 | CYP2C19 (0.61) | CYP2C19CYP3A4GRK2CYP2C9 | |
| SCHEMBL21611982 | 0.76 | CYP2C19 (0.54) | CYP2C19CYP3A4GRK2PDE10ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353606-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-11-18 | — | — | US | disclosed |
| EP-3818045-A1 | PQSR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020007938-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-01-09 | — | — | WO | disclosed |
| WO-2020007938-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353606-A1 | PqsR INVERSE AGONISTS | QRFPR, P2RY11, QARS1 | CYP2C19 1824/4885CYP3A4 3080/4885GRK2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.